01276.HK
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
HKD 46.26
+4.14%Sep 20, 2026, 05:57 UTC
Hengrui Pharmaceuticals reported R&D spending of 4.605 billion yuan in the first half of 2026, up 18.96% year on year and equal to 29.8% of revenue.
Source:Sep 20, 2026, 05:57 UTC
Hengrui Pharmaceuticals reported that in the first half of 2026 its innovative-drug sales revenue rose to 8.809 billion yuan, 63.16% of drug sales revenue, with non-oncology innovative-drug revenue up 73.97%.
Source:Sep 20, 2026, 05:57 UTC
Hengrui Pharmaceuticals received Chinese approval in 2026 for four Class 1 innovative drugs — rilafusp alfa injection, luzonorestat sodium tablets, insulin sudi injection and fumurate likangcopan capsules — plus the Class 2 new drug cyclosporine eye drops (IV).
Source:Sep 17, 2026, 09:10 UTC
Hengrui Medicine repurchased 335,000 A-shares for the first time on September 17, 2026, at prices between 43.10 and 43.58 yuan per share, paying a total of 14.5036 million yuan under its 1-2 billion yuan buyback program.
Sep 15, 2026, 09:09 UTC
BlackRock raised its stake in Hengrui Pharmaceuticals H-shares from 6.56% to 7.17% on September 10.
Source:Sep 15, 2026, 08:35 UTC
Hengrui Medicine's subsidiary Fujian Shengdi Pharmaceutical received approval from China's National Medical Products Administration to conduct clinical trials of HRS-4139 tablets for moderate-to-severe plaque psoriasis.
Source:Sep 15, 2026, 08:35 UTC
Hengrui Medicine's subsidiary Guangdong Hengrui Pharmaceutical received NMPA approval to launch a Phase III clinical trial of injectable recaticimab in adults with intracranial atherosclerotic stenosis to reduce stroke recurrence risk.
Sep 14, 2026, 09:46 UTC
Hengrui Medicine's subsidiary Beijing Shengdi Pharmaceutical received acceptance from China's National Medical Products Administration for the marketing application of its Class 1 innovative drug SHR-2004 injection, a factor XI monoclonal antibody for preventing venous thromboembolism in adults undergoing elective knee replacement surgery.
Source:Sep 10, 2026, 06:33 UTC
Hengrui Medicine held its 2026 interim results briefing on September 10, 2026, where it discussed its pipeline outlook.
Source:Sep 7, 2026, 10:58 UTC
Hengrui Medicine announced it will hold an extraordinary general meeting on September 24, 2026 to consider adopting a 2026 H-share plan, and will suspend H-share registration from September 21 to 24, 2026.
Source:Sep 7, 2026, 09:48 UTC
On September 2, BlackRock increased its long position in Jiangsu Hengrui Pharmaceuticals H-shares from 5.92% to 7.21%, as disclosed by the Hong Kong Stock Exchange.
Source:Aug 26, 2026, 10:33 UTC
JPMorgan Chase increased its long position in Jiangsu Hengrui Pharmaceuticals H shares from 9.59% to 10.69% on August 21, as disclosed by the Hong Kong Stock Exchange.
Source:Aug 25, 2026, 09:06 UTC
GIC Private Limited increased its stake in Hengrui Medicine's H shares from 14.29% to 15.70% on August 20, 2026, with an average purchase price of HKD 50.5655 per share.
Source:Aug 19, 2026, 11:39 UTC
Hengrui Medicine announced its first-half 2026 results with revenue of 15.456 billion yuan, down 1.94% year-on-year, and net profit attributable to shareholders of 4.465 billion yuan, up 0.34%.
Aug 14, 2026, 10:25 UTC
Hengrui Medicine repurchased 488,000 A-shares for 25.8 million yuan on August 14, 2026, for its employee stock ownership plan.
Source:Aug 13, 2026, 09:39 UTC
Hengrui Medicine repurchased 405,000 A-shares for 21.86 million yuan on August 13, 2026, for its employee stock ownership plan.
Source:Aug 10, 2026, 09:40 UTC
Hengrui Medicine repurchased 200,000 A-shares for 10.7833 million yuan on August 10, 2026, via centralized bidding for its employee stock ownership plan.
Source:Jul 31, 2026, 09:11 UTC
Capital Group increased its stake in Hengrui Medicine H-shares on July 29, raising its holding from 9.86% to 10.04%, with an average purchase price of 57.9041 HKD.
Source:Jul 30, 2026, 01:42 UTC
China's National Medical Products Administration approved four innovative drugs for market launch.
Source:Jul 28, 2026, 07:25 UTC
Jiangsu Hengrui Medicine Co., Ltd. established a wholly-owned subsidiary Zhejiang Hengrui Medicine Co., Ltd. in Zhejiang with a registered capital of 50 million yuan.
Jul 28, 2026, 02:02 UTC
CSPC Pharmaceutical Group's marketing application for injectable sirolimus (albumin-bound) was accepted by the National Medical Products Administration and granted priority review.
Source:Jul 28, 2026, 01:36 UTC
Ascletis Pharma announced that its once-monthly subcutaneous triple agonist peptide ASC37 showed superior weight loss effects in a diet-induced obesity mouse model.
Source:Jun 5, 2026, 23:32 UTC
Hengrui Pharma and Kailera Therapeutics presented clinical data for ribupatide at the ADA 2026 conference.
Source:Jun 1, 2026, 06:00 UTC
Hengrui Pharma presented more than 90 oncology studies at ASCO 2026, highlighting progress across multiple tumor types.
Source: